Discord Call: Tuesday, Sept 6thUnderstanding it's still a week and a bit to go, it's just about time to start sending DM subject questions, by email, at: investors@datametrex.com
I've sent the following but omitted to ask about an update on Europe - MG alluded to, in a previous Discord, that we should be hearing news about our operations across the pond. Perhaps if someone else writes to DM, they may want to raise this with them, avoiding me sending another email...
In the meantime, here are the questions I've sent, understanding limited time and, potentially, the "material" nature of some of these may lead to some not being addressed:
1. South Korea. Any updates on SK legacy contracts? (i.e. NRs were issued in May, Oct, Nov 21 and Jan 22 but no news since). I'm asking in the context of perhaps underwhelming Q2 IT income results.
2. Medicall.
a. Medicall vs Screenpro. A couple of years ago DM had to spin out COVID-testing to Screenpro as the TSX.V raised concerns about an AI company (tech) running a health vertical. Can you elaborate as to how that was different to the current status with Medicall (i.e. especially given that DM is bringing on board health professionals, diagnostic tools etc)?
b. Medicall business model. I was under the impression, given DM's Screenpro experience, that Medicall was going to be an app-driven SaaS sold to networks of healthcare providers. Hence that it would not entail bringing on board staff (i.e. healthcare practitioners) other than, perhaps, in advisory roles (i.e. help oversee product implementation and improvements, catering to the Clients (i.e. registered health professionals). I also didn't expect DM to directly reach out to individual customers (i.e. patients) but that it would, rather, generate income through a SaaS model. Could you clarify DM's business model for Medicall?
3. TSX uplisting. Any clearer insight as to when the uplist may take place? Could the Medicall point (2) raised be contributing to the delay in the graduation?
4. DM EVS. Not unlike for Medicall, I was under the impression the DM EVS business model would be mostly SaaS-driven and top-light (i.e. that DM may sell EVS solutions but not manage them per se). Can you elaborate on DM's business model in that regard - understanding it may be a work in progress?..
5. Nexalogy $40M contract.
a. Milestones. MG previously declared that the Nexalogy contract milestones were expected to be completed over 3-6 month periods. Given that the last subject NR was released end-March, can we reasonably expect an update on Milestone 2 by end-Sept?
| Making Sense of Social Media Chatter with a Modular Platform | Nexalogy | $2,645,000.00 | Component 2 |
| Provenant - Tracing Mass Manipulation in the Social Media War on Influence | Uncharted Software Inc. | $2,641,145.09 | Component 2 |